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ABSTRACT
Homozygous inactivating mutations in DMP1 (dentin matrix protein 1), the gene encoding a noncollagenous bone matrix protein
expressed in osteoblasts and osteocytes, cause autosomal recessive hypophosphatemia (ARHP). Herein we describe a family with ARHP
owing to a novel homozygous DMP1 mutation and provide a detailed description of the associated skeletal dysplasia and carrier
phenotype. The two adult patients with ARHP, a 78-year-old man and his 66-year-old sister, have suffered from bone pain and lower
extremity varus deformities since early childhood. With increasing age, both patients developed severe joint pain, contractures, and
complete immobilization of the spine. Radiographs showed short and deformed long bones, significant cranial hyperostosis,
enthesopathies, and calcifications of the paraspinal ligaments. Biochemistries were consistent with hypophosphatemia owing to renal
phosphate wasting; markers of bone turnover and serum fibroblast growth factor 23 (FGF-23) levels were increased significantly.
Nucleotide sequence analysis of DMP1 revealed a novel homozygous mutation at the splice acceptor junction of exon 6 (IVS5-1G>A).
Two heterozygous carriers of the mutation also showed mild hypophosphatemia, and bone biopsy in one of these individuals showed
focal areas of osteomalacia. In bone, DMP1 expression was absent in the homozygote but normal in the heterozygote, whereas FGF-23
expression was increased in both subjects but higher in the ARHP patient. The clinical and laboratory observations in this family confirm
that DMP1 has an important role in normal skeletal development and mineral homeostasis. The skeletal phenotype in ARHP may be
significantly more severe than in other forms of hypophosphatemic rickets.  2010 American Society for Bone and Mineral Research.
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Introduction
H
ypophosphatemia owing to renal phosphate wasting is
inherited most frequently as an X-linked dominant disorder
(XLH), which is caused by dominant mutations in the PHEX gene,
or as an autosomal dominant condition (ADHR), which is caused
by heterozygous mutations in the fibroblast growth factor 23
gene (FGF23).
(1) Recently, homozygous mutations in the gene
encoding DMP1 (dentin matrix protein 1), a noncollagenous
phosphoprotein, were identified as the cause of an autosomal
recessive form of hypophosphatemia (ARHP).
(2,3)
Dmp1 was identified originally from a rat incisor cDNA library
and was shown to play an important role in late-stage
dentinogenesis.
(4) Further studies have shown that DMP1 is
expressed mainly in mineralizing tissues.
(5,6) Dmp1-deficient
mice have no apparent abnormalities in prenatal bone
development. However, postnatal growth plate development
is severely impaired and results in a chondrodysplasia-like
phenotype characterized by short and widened long bones with
flaired and irregular metaphyses and delayed and malformed
ossification centers.
(3,7) Microscopically, the growth plates are
expanded and disorganized with increased proliferation of
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2165chondrocytes, impaired chondrocyte apoptosis, poor calcifica-
tion of cartilage matrix, and delayed blood vessel invasion.
(3,7)
TheskeletalabnormalitiesinDmp1-nullmiceare100%penetrant
and worsen with age, whereas heterozygous mutation carriers
show no skeletal abnormalities.
(7)
Ling and colleagues
(8) showed that Dmp1-null mice have a
decreased mineral-to-matrix ratio in bones and that DMP1 has
both direct and indirect roles in the regulation of postnatal
skeletal mineralization. More importantly, Dmp1-null animals
revealed significantly lower serum phosphorus concentrations
than wild-type controls owing to increased urinary phosphate
excretion, which is associated with increased FGF-23 levels.
(9)
Subsequent studies showed that the hypophosphatemia and
bone abnormalities in Dmp1-null animals can be normalized by
the transgenic expression of the full-length or the C-terminal 57-
kDa fragment of DMP1 under the control of the DMP1 promoter,
suggesting that this osteocyte/osteoblast-derived protein has a
major role in reducing FGF-23 synthesis and/or secretion.
(10)
Consistent with these findings in mice, Feng and colleagues
(3)
and Lorenz-Depiereux and colleagues
(2) recently described
several unrelated families with autosomal recessive hypophos-
phatemia caused by homozygous loss-of-function mutations in
DMP1. The affected individuals had clinical findings consistent
with rickets/osteomalacia and metabolic profiles consistent with
hypophosphatemia owing to renal phosphate wasting, normal
urinary calcium excretion, normal parathyroid function, and
levels of 1,25-dihydroxyvitamin D [1,25(OH)2D3] that were
inappropriately normal for the degree of hypophosphatemia.
They also had increased or inappropriately normal serum FGF-23
concentrations.
(2,3) Bone biopsy in an affected individual
showed, in addition to severe osteomalacia, increased bone
volume.
(3)
We now describe a Finnish family with two adults affected
by ARHP owing to a novel homozygous DMP1 mutation. The
homozygous patients had a severe phenotype with skeletal
dysplasia,whereastheheterozygousindividualsapparentlywere




The family with autosomal recessive hypophosphatemic rickets
was identified through the Finnish Skeletal Dysplasia Registry.
The two affected adult siblings and two clinically unaffected
children, both obligate mutation carriers, were invited to
participate. The Helsinki University Hospital Ethics Review Board
approved the protocol, and written informed consent was
obtained from all participants.
Clinical data were collected from medical records. Patients
were assessed clinically, and blood and urine samples were
obtained for measurement of different parameters of calcium
(Ca) and phosphorus (Pi) homeostasis and of bone metabolism.
Plasma concentrations of Pi, Ca, and alkaline phosphatase
(ALP) and urine concentrations of Pi, Ca, and creatinine (Crea)
were determined by standard assays. Serum parathyroid
hormone (PTH) was measured by solid-phase enzyme-labeled
chemiluminescent immunometric assay (IMMULITE 2000, DPD,
Diagnostic Products Corporation, Los Angeles, CA, USA). Serum
1,25(OH)2D3 was determined by RIA (Gamma-B 1,25-Dihydroxy
Vitamin D RIA, Immunodiagnostic Systems, Boldon, UK) and
serum 25-hydroxyvitamin D [25(OH)D] was determined by high-
performance liquid chromatography.
Serum concentrations of N-terminal propeptide of type I
procollagen (PINP), a bone-formation marker, and C-terminal
telopeptide of type I collagen (ICTP), a bone-resorption marker,
were measured by competitive RIA (UniQ PINP/ICTP RIA, Orion
Diagnostica, Espoo, Finland). The second fasting morning void
was collected for measurement of the bone-resorption marker
urinaryN-terminaltelopeptideoftypeIcollagen(U-NTX).Analyses
were performed with a luminoimmunologic assay (Vitros ECi,
NTx Reagent Pack, Ortho-Clinical Diagnostics, New York, NY,
USA), and the results were expressed as nanomoles of bone
collagen equivalents (BCEs) per millimole of creatinine. FGF-23
was measured by a two-site immunometric assay (Immutopics,
San Capistrano, CA, USA) that uses antibodies directed against
two C-terminal epitopes of human FGF-23 and thus detects
intact FGF-23 as well as a C-terminal fragment thereof.
(11)
Radiologic evaluation
Previously obtained radiographs and other available imaging
studies were reviewed. A full radiographic skeletal survey was
obtained for the two affected adults, and a partial skeletal survey
was obtained for the two obligate carriers. Bone mineral density
(BMD) was measured with dual-energy X-ray absorptiometry




A transilial bone biopsy was obtained from one subject, an
obligate carrier (individual 3), with a bone biopsy needle with an
inner diameter of 7.5mm (Rochester Bone Biopsy, Medical
Innovations International, Inc., Rochester, MN, USA) following
two courses with an oral tetracycline, which were separated by a
10-day period. The biopsy was performed 4 days after the last
tetracycline administration. In addition, a previously obtained
transilial bone biopsy of a female patient with ARHP (patient 1)
was reanalyzed. Bone histomorphometric analysis was con-
ducted in the Bone Histomorphometry Laboratory at UCLA. All
parameters were analyzed under  200 magnification using the
OsteoMetrics system (OsteoMetrics, Decatur, GA, USA), and the
results were compared with normative data.
(12) The samples
were stained with toluidine blue stain (pH 7.4). Mineralized bone
was defined by dark-blue areas; pale-blue seams of at least
1.5mm in width were included in the osteoid measurements. For
dynamic histomorphometric analysis, mineralizing surface per
bone surface and mineral apposition rate were measured in
unstained sections under ultraviolet (UV) light using a B-2A set
longpass filter consisting of an excitation filter ranging from 450
to 490nm, a barrier filter at 515nm, and a dichroic mirror at
500nm. Nomenclature as well as all abbreviations and standard
formulas follow the recommendations by the American Society
for Bone and Mineral Research.
(13)
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Thetechniquefortheimmunohistochemical detectionofFGF-23
and DMP1 in partially decalcified bone was adapted from a
previously reported method.
(14,15) In brief, two adjacent 5-mm
sections of bone tissue were placed side by side on each slide.
Sections were deplastified in xylene and chloroform, rehydrated
in graded alcohol solutions, and partially decalcified in 1% acetic
acid. Endogenous peroxidase activity was quenched in 3%
hydrogen peroxide–methanol solution. Nonspecific binding was
blocked by an avidin-biotin solution and 5% normal horse serum
with 1% bovine serum albumin. Sections then were incubated
with either affinity-purified polyclonal goat anti-human FGF-23
(raised against amino acids 225 to 244; Immutopics) or
monoclonal anti-human DMP1 (LFMb31) (raised against amino
acids 62 to 513; kindly provided by Dr Larry Fisher, NIH) primary
antibody overnight at 48C in a humidified chamber. Subse-
quently, samples were incubated with specific biotinylated
secondary antibody (Vector, Burlingame, CA, USA) followed by
ABComplex/HRP complex (ABC Kit, Vector) and developed using
the AEC Kit (Vector). Sections then were counterstained with
Mayer hematoxylin (Sigma-Aldrich, St. Louis, MO, USA). Iliac crest
bone biopsy specimens from four adolescent or young-adult
subjects with normal renal function served as controls. Negative
controls were performed for each bone section by omitting the
primary antibody. The specimen sections were batched; thus
immunohistochemistry was performed simultaneously on all
patient specimens, along with normal and negative controls.
Genetic studies
DNA was extracted by standard methods from peripheral blood
lymphocytes.
(16) Nucleotide sequence analysis of the PCR-
amplified exons encoding DMP1 and the flanking intronic
regions were performed at the Harvard-Partners Center for
Genetics and Genomics (Boston, MA, USA). To confirm the
presence of the identified mutation, DMP1 exon 6 was amplified
by using 5’-CGGTTCCTGGAATACTGACC-3’ as the forward primer
and 5’-GGAGTTTCCCCTTTCACTCC-3’ as the reverse primer to
obtaina551-bpPCRproduct,whichthenwasincubated withthe




The pedigree of the family is shown in Fig. 1. The proband,
patient 1, a 66-year-old woman (Fig. 2A) was born to healthy
parents with no known consanguinity, but both parents
originated from the same remote island in southeastern Finland;
she has five healthy siblings and one affected brother (patient 2).
This patient has had bone pain and knee varus deformities since
early childhood. Lower limb osteotomies were first performed at
age 6 years, and subsequently, numerous (>30) orthopedic
procedures were needed to correct lower limb deformities, to
repair bilateral femoral neck fractures, and to treat cervical
spinal stenosis. Total-hip replacements were performed at
57 and 61 years, respectively. The patient had significant dental
problems, with recurrent gingival abscess formation, and
Fig. 1. Pedigree of the family with ARHP. Black symbols¼affected
individuals; white symbols with black dots¼carriers of the mutation.
Fig. 2. Photographs of the two adult ARHP patients. (A) Patient 1 at the age of 66 years. (B) Patient 2 at the age of 78 years.
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deficit. Hypophosphatemiawasdiagnosedattheageof20years,
and she was treated periodically with oral phosphate and active
vitamin D analogues. Her height, when assessed for this study,
was 130cm. She has complete spinal ankylosis with calcification
of the spinal ligaments and dural ectasia, lower limb deformities,
and contractures.
Patient 2, a 78-year-old man (Fig. 2B), developed bone pain
and knee varus deformity in early childhood and was first
evaluated at age 3 years. Lower limb osteotomies were
performed at 18 years, but hypophosphatemia was not
diagnosed until adulthood, and he never received treatment
withoralphosphateorvitaminDanalogues.Withincreasingage,
he developed severe joint pain and contractures, calcifications of
the paraspinal ligaments leading to complete immobilization of
the spine, and significant cranial hyperostosis. He has a hearing
deficit and significant dental problems related to abscesses. His
maximum adult height was 150cm. When assessed for this
study,hemeasured138cminheightandwaswheelchair-bound.
Other illnesses included hypertension and prostate cancer,
diagnosed at age 66.
Individuals 3 and 4 are healthy 38-year-old adults, the twin
children of patient 2, who thus are heterozygous carriers of the
identified DMP1 mutation; both had no complaints, no skeletal
abnormalities, and no history of other medical problems.
Genetic findings
Molecular genetic analysis of the DMP1 gene revealed a novel
mutation at the splice acceptor junction of exon 6 (IVS5-1G>A).
Patients 1 and 2 are homozygous and individuals 3 and 4 are
heterozygous carriers of the mutation. The nucleotide change,
which was absent in 148 control chromosomes, is predicted to
alter pre-mRNA splicing. Several potential downstream cryptic
splice acceptor sites were identified that are likely to result in a
shift in the open-reading frame if the resulting message is stable.
Biochemical findings
Biochemical findings of the four assessed subjects are presented
in Table 1. For both patients with the homozygous DMP1
mutations, blood and urine biochemistries were consistent with
hypophosphatemia owing to renal phosphate wasting. Markers
of bone turnover were increased significantly, and 1,25(OH)2D3
concentration was inappropriately low for the degree of
hypophosphatemia. Serum FGF-23 was increased in both
patients. The heterozygous carriers of the mutation had mild
hypophosphatemia and increased urinary phosphate excretion,
whereas other biochemistries were normal (Table 1).
Radiologic evaluation
The main features in the skeletal radiographs were (1) poor bone
architecture—including abnormal bone size and shape and
abnormal cortical and cancellous bone patterns—affecting all
bones, (2) generalized degenerative arthritis (axial and appendi-
cular) with loss of articular cartilage and intervertebral disks with
fusion of joints with bone, and (3) extension of ossification from
the bones into the soft tissues and interosseous membranes
(Table 2). The radiographic findings were very similar in the two
homozygote patients (Fig. 3), and both showed abnormal bone
structure, short and deformed long bones, significant cranial
hyperostosis, enthesopathies, and calcifications of the spinal
ligaments in the cervical, thoracic, and lumbar spine (Fig. 3A, B);
patient 2 had a pathologic fracture of the left femoral neck
(Fig. 3G). Spinal MRI of patient 1 showed a large dural ectasia in
the midthoracic and lumbar spine (Fig. 3C). The two hetero-
zygous carriers of the mutation had no abnormalities on skeletal
radiographs.
Review of earlier radiographs of patient 1 showed metaphy-
seal irregularities consistent with mild rickets, delayed bone
maturation, and significant lower limb deformities (Fig. 4). Even
attheageof19years,mildparaspinalcalcificationswerepresent.
Table 1. Biochemical and Bone Densitometry Findings in the Subjects With Homozygous or Heterozygous DMP1 Mutations
Parameter Subject 1 Subject 2 Subject 3 Subject 4 Normal
Gender/age (years) F/66 M/78 M/38 F/38
Genotype Homozygous Homozygous Heterozygous Heterozygous
Height (cm) 130 138 173 167
Ca (mmol/L) 2.21 2.25 2.36 2.15 2.15–2.51
Pi (mmol/L) 0.60 0.48 0.48 0.70 0.71–1.23
ALP (U/L) 191 290 56 37 35–105
P-PTH (ng/L) 89 93 69 61 8–73
25(OH)D (nmol/L) 23 38 58 86 >40
1,25(OH)2D3 (pmol/L) 77 98 138 105 48–110
TmP/GFR 0.47 0.42 0.44 0.60 >0.80
U-INTP (nmol/mmol Cr) 276 261 28 43 <65
PINP (mg/L) 156 84 37 36 19–84
ICTP (mg/L) 10.2 11.1 1.8 3.1 1.5–5.0
FGF-23 (RU/ml) 305 182 53 41 <150
Lumbar spine BMD Z-score NA NA  1.5  0.5 >–1.0
Femoral neck BMD Z-score NA NA  1.3  0.7 >–1.0
Note: Supranormal values are in bold; subnormal values are underlined.
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(patient 1) prevented BMD assessment in the homozygous
individuals. One of the two heterozygote children showed
reduced BMD suggestive of mild osteopenia (Table 1).
Bone biopsy findings
Bone histomorphometry findings in patient 1 and her healthy
son (individual 3) are presented in Table 3, and the histology is
shown in Fig. 5. Patient 1, affected by ARHP, demonstrated very
severe osteomalacia with marked increases in all osteoid
parameters (ie, osteoid volume, surface, and thickness). No
double-tetracycline labels were observed in this patient, and
most of the single labels were broad and diffuse. The number
of osteoblasts was within the normal range, but the number
of osteoclasts was decreased. In contrast, individual 3, a
heterozygous carrier of the DMP1 mutation, displayed normal
histomorphometric indices of osteoid accumulation. However,
despite normal calculated bone indices, three to four focal areas
of increased osteoid thickness were observed (Fig. 5). Tetra-
cyclineuptakewasabnormalinpatient1,thatis,broadanddiffuse,
and mineralization lag time (MLT) was increased, whereas
measures of bone formation—mineralization apposition rate
(MAR), mineralizing surface (MS/BS), and bone-formation rate
(BFR)—were reduced compared with normal values. Osteoblast
and osteoclast numbers also were decreased.
Figure6displaystheimmunohistochemical expressionofFGF-
23 and DMP1. FGF-23 was increased in both patients; however,
FGF-23 expression was markedly higher in the ARHP patient
(patient1)thanintheheterozygouscarrieroftheDMP1mutation
(individual 3). DMP1 protein was absent from bone of patient 1,
and DMP1 expression in individual 3 was indistinguishable from
that observed in controls.
Discussion
We describe genetic and phenotypic findings in a not previously
described family with autosomal recessive hypophosphatemia
that is caused by a novel homozygous DMP1 mutation. The
clinical and laboratory observations in this family confirm that
DMP1 has an important role in normal skeletal development and
mineral homeostasis. Homozygous DMP1 mutations result in
hypophosphatemia owing to increased renal phosphate excre-
tion and in a severe skeletal phenotype with short stature,
deformed bones, abnormal bone structure, pathologic fractures,
and severe enthesopathies. Furthermore, our findings suggest
that DMP1 mutation carriers also may have a clinically significant
phenotype.
Table 2. RadiographicCharacteristics ofSkeletalDysplasiaSecondarytotheIdentifiedHomozygous
DMP1 Mutation
Skeletal site Characteristic features
Skull Thick calvarium and skull base
Midface hypoplasia, prominent mandible
Early loss of teeth
Cervial spine Ankylosis of the cervical spine
Disappearance of the intervertebral disks
Posterior fusion of the spinous processes
Ossification of the anterior longitudinal ligament
Ossification of the laryngeal cartilages
Thoracic and lumbar spine Tall vertebral bodies/vertebral compression
Abnormal laminae and spinous processes
Loss of disk space
Ossification and extensive bony ankylosis
Ossification of the paraspinal muscles and ligaments
Scoliosis and kyphosis
Pelvis Abnormal shape and bony architecture
Loss of articular cartilage and bony ankylosis of the sacroiliac joints
Deep acetabulae
Degeneration of the hip joint space, osteophytes, ankylosis
Upper and lower limbs Short, broad, and curved tubular bones
Poorly developed cortices
Calcification of the forearm interosseus membrane
Ossification of tendon attachments
Joint space narrowing with degenerative arthritis
Pathologic lower limb fractures
Chest Narrow chest
Wide clavicles
Degenerative arthritis of the shoulders and acromioclavicular joints
SKELETAL PHENOTYPE IN DMP1 HYPOPHOSPHATEMIA Journal of Bone and Mineral Research 2169Previous studies have suggested multiple functions for DMP1
in postnatal skeletal development and chondrogenesis. DMP1 is
expressed mainly in mineralizing tissues in hypertrophic
chondrocytes, osteoblasts, and osteocytes and is required for
normal growth plate and epiphyseal development.
(5,6) Ablation
of the Dmp1 gene in mice results in a chondrodysplasia-like
phenotype starting several days to weeks postnatally.
(3,7) The
growth plates are abnormally expanded and disorganized, and
endochondral ossification is decreased. The metaphyses fail to
lengthen normally, and the metaphyseal ends of long bones are




age. The skeletal phenotype in our patients with ARHP was
Fig. 3. RadiographicfindingsinthetwoARHPpatientswiththehomozygousDMP1mutation.Calcifications(arrows)ofthespinalligamentsinthethoracic
(A) and lumbar spine (B) in patient 1. Spinal MRI of patient 1 showed a large dural ectasia (arrow) in the midthoracic and lumbar spine (C). Abnormal bone
structureandshortanddeformedlongbones(D,humerus;E,radiusandulna;F,hand;H,tibiaandfibula)inpatient1.Patient2hadapathologicfractureof
the left femoral neck (G). Both patients had significant cranial hyperostosis (I, patient 1; J, patient 2).
2170 Journal of Bone and Mineral Research MA ¨KITIE ET AL.similar to that seen in Dmp1-deficient mice. The patients
homozygous for the DMP1 mutation had abnormal bone
structure as well as short and deformed long bones. The skeletal
abnormalities became apparent in early childhood and
progressed with age, resulting in severe skeletal dysplasia with
deformities and short stature. No radiographs were available
from early childhood for the two homozygous carriers of the
DMP1 mutation. However, radiographs obtained between the
ages of 12 and 19 years were consistent with delayed skeletal
maturation and delayed closure of the growth plate in one of the
patients.
In addition to the observed changes in the metaphyseal,
epiphyseal, and diaphyseal areas of tubular bones, both patients
had severe generalized degenerative arthritis (axial and
appendicular) with loss of articular cartilage and intervertebral
disk space. They also had significant cranial hyperostosis,
enthesopathies, and calcifications of the spinal ligaments in
the cervical, thoracic, and lumbar spine. The mechanism leading
to the degenerative joint disease and ankylosis is unclear, but
occurrence of these findings may indicate that DMP1 is required
for normal long-term articular cartilage health. In fact, Ye and
colleagues showed in mice that Dmp1 is essential for normal
development of secondary ossification centers and that ablation
of the Dmp1 gene leads to delayed and malformed epiphyses
followed by joint destruction.
(7) Furthermore, altered architec-
ture of the underlying subchondral bone may contribute to
destruction of articular cartilage.
(17) Ossification of the adjoining
soft tissues occurred to an extent that has not been described
previously in association with DMP1 mutations and may be
a reflection of the long-standing disease process. In contrast
to the hypophosphatemia owing to an FGF-23-mediated
increase in urinary phosphate excretion observed in patients
lacking functional DMP1, GALNT3 and FGF23 mutations result
in hyperphosphatemia owing to inappropriately low urinary
phosphate excretion and low intact FGF-23 levels leading to the
development of tumoral calcinosis. The severe enthesopathies
observed in our patients are similar to those observed in other
hypophosphatemic disorders, but these changes are usually
Fig. 3. (Continued)
Fig. 4. Radiographs of patient 1 obtained between 1952 and 1969. (A) Severe coxa vara (12 years) and (B) lower leg deformity (14 years). (C) Delayed
closure of epiphyses and calcification of the forearm interosseus membrane (18 years). (D) Paraspinal calcifications without deformities of the vertebral
column (29 years).
SKELETAL PHENOTYPE IN DMP1 HYPOPHOSPHATEMIA Journal of Bone and Mineral Research 2171Table 3. Bone Histomorphometry Findings in Patient 1 (Female), Who Carries a Homozygous DMP1 Mutation, and Her Son, Individual 3
(Male), Who Is Heterozygous for the Mutation
Normal range





Bone volume/tissue volume (BV/TV) (%) 27.47 30.17 16 4.2 22.0 3.9
Osteoid volume/bone volume (OV/BV) (%) 57.7 1.86 1.5 0.6 3.5 1.9
Osteoid thickness (O.Th) (mm) 37.8 9.34 8.2 3.7 9.7 4.6
Osteoid surface/bone surface (OS/BS) (%) 84.55 14.16 13.1 4.1 14.0 4.6
Osteoblast surface/bone surface (Ob.S/BS) (%) 1.18 0.54 4.3 1.8 6.0 1.1
Eroded surface/bone surface (ES/BS) (%) 0 1.23 4.4 2 4.5 1.9
Osteoclast surface/bone surface (Oc.S/BS) (%) 0 0.264 0.8 0.5 0.6 0.4
Trabecular thickness (Tb.Th) (mm) 103.8 141.14 139.0 38 138 24
Trabecular separation (Tb.Sp) (mm) 273.98 326.73 602 171 494 82
Trabecular number (Tb.N) (/mm) 2.64 2.14 1.4 0.4 1.7 0.4
Mineralizing surface/bone surface (MS/BS) (%) 0.0001 2.9 7.2 4.7 7.5 3.6
Mineral apposition rate (MAR) (mm/day) 0.0001 0.45 0.68 0.12 0.76 0.18
Bone formation rate/bone surface (BFR/BS) (mm
3/mm
2/year) 0.0001 4.9 18 3 20.8 4
Adjusted apposition rate (Aj.AR) (mm/day) 0.0001 0.1 0.56 0.21 0.63 0.34
Mineralization lag time (MLT) (days) 1 97 20.4 8.1 18.4 6.3
Note: Reference values given for each parameter as mean SD.
Fig. 5. Bone histology, toluidine blue staining (upper panel). Dark-blue staining indicates mineralized bone; unmineralized osteoid stains pale blue.
Osteoid accumulation was increased significantly throughout trabecular bone in patient 1 (A), whereas focal areas of increased osteoid thickness were
evident in individual 3 (B). Tetracycline uptake (lower panel) is diffuse and abnormal in patient 1 (A), whereas double and single labels are observed in
individual 3 (B).
2172 Journal of Bone and Mineral Research MA ¨KITIE ET AL.much milder. Only one of our patients had been treated with
phosphate, implying that the significant extraskeletal ossifica-
tionsarenottreatment-relatedbutdevelopthroughanother,still
unknown mechanism.
Farrow and colleagues described a family with ARHP caused
by a large biallelic deletion that removed most portions of the
DMP1gene.
(18)Thetwo affectedindividualsinthisstudysuffered
from marked hypophosphatemia, persistent osteomalacia,
stunted growth, nerve deafness, facial and dental abnormalities,
and learning disabilities. Furthermore, Turan and colleagues
(19)
described a family with ARHP caused by a novel homozygous
frameshift mutation (c.485Tdel; p.Glu163ArgfsX53) in exon 6
resulting in a premature stop codon. The affected children had,
in addition to biochemical and radiographic findings typical for
rickets, short and broad long bones and dysplastic distal
phalanges. These skeletal changes are similar to but less severe
than those observed in our patients. The profound skeletal
abnormalities observed in our patients and the associated
hearing impairment, as well as the dental anomalies, suggest
that the phenotypic manifestations in our ARHP patients are
significantly more severe than those observed in other forms of
hypophosphatemic rickets.
One of the patients had a large dural ectasia, but it is unclear
whether DMP1 is normally expressed in the dura mater and
whether the lack of DMP1 in this tissue and/or hypopho-
sphatemia contribute to the development of dural ectasia in
ARHP. Dural ectasia occurs in genetic conditions with skeletal or
connective tissue abnormalities, including Marfan syndrome,
neurofibromatosis, and Ehlers-Danlos syndrome; in Marfan
syndrome, dural ectasia associates with low BMD.
(20,21) Dural
ectasia also may occur in ankylosing spondylitis.
(22) It has been
proposed that the pulsatile changes in cerebrospinal fluid
pressure lead to scalloping of the vertebrae, enlargement of the
intervertebral foramina, and dural ectasia in a dural sac with
abnormal elasticity and/or residual adhesions.
(22)
The bones of Dmp1
 /þ heterozygote mice were indistinguish-
able from those of wild-type littermates. Furthermore, both
groups of animals showed comparable rates of weight gain and
growth, as well as similar radiographic and histologic appear-
ance, suggesting that the loss of a single copy of the Dmp1 gene
has no apparent effect on skeletal development.
(8) Consistent
withthesefindingsinmice,thetwoheterozygous childrenofour
ARHP patients showed normal stature, absence of skeletal
deformities, and normal long bone and spinal radiographs. It
remains unknown, however, whether heterozygous carriers of
the DMP1 mutation have an increased risk of developing early
degenerative arthritis. Interestingly, both heterozygous indivi-
duals showed evidence of mild hypophosphatemia owing to
increased urinary phosphate excretion. The calculated histologic
indices of osteoid accumulation were normal when bone of
heterozygous carrier 3 was evaluated, although this individual
displayed evidence of focal osteomalacia, decreased number of
osteoblasts,andanabnormal mineralizationrate.Togetherthese
findings suggest a subtle mineralization defect, even in the
heterozygous carriers, that may be related to a decrease in
osteoblast number and/or osteoblast dysfunction. Consistent
with a mineralization defect, bone FGF-23 expression appeared
to be increased in this individual compared with bone samples
from four healthy controls, whereas DMP1 expression was
indistinguishable from that of controls. This suggested that the
apparently normal amounts of DMP1 (ie, ‘‘inappropriately
normal’’ amounts of the protein) were unable to suppress
excess FGF-23 expression.
FGF-23, produced by osteocytes and osteoblasts, appears to
be the key regulator of renal phosphate reabsorption and
1,25(OH)2D3 synthesis,
(1) and increased circulating levels of this
phosphaturic hormone are likely responsible for the biochemical
and skeletal abnormalities observed in ARHP.
(9) Osteoblastic
bone formation modulates FGF-23 production, and regulation of
FGF-23 is inversely linked to the production of bone matrix
proteins, especially DMP1.
(23) In Dmp1-null animals, hypophos-
phatemia and bone abnormalities can be normalized by
transgenic expression of DMP1.
(10) Furthermore, Dmp1-null
mice with superimposed FGF-23 deficiency show no hypophos-
Fig. 6. Immunohistochemical staining of DMP1 (upper panel) and FGF-23 (lower panel) expression in bone biopsy specimens of patient 1 (homozygote),
individual 3 (heterozygote), and a normal control individual. DMP1 expression was absent in bone from patient 1, whereas the bone specimen obtained
from individual 3 revealed DMP1 expression that is indistinguishable from that of controls. FGF-23 expression was increased in both subjects but to a
greater degree in patient 1 than in her son, individual 3. TB¼trabecular bone; BM¼bone marrow.
SKELETAL PHENOTYPE IN DMP1 HYPOPHOSPHATEMIA Journal of Bone and Mineral Research 2173phatemia or 1,25(OH)2D3 deficiency and have normal skeletal
mineralization.
(9) It is therefore conceivable that, similar to other
forms of hypophosphatemic rickets, administration of conven-
tional phosphate–vitamin D analogue treatment during child-
hood could have partially corrected the skeletal phenotype in
our patients with ARHP. Ideally, however, treatment should
be targeted to FGF-23, potentially through the application of
anti-FGF-23 antibodies, to mitigate the actions of endogenous
FGF-23.
(24)
In conclusion, the homozygous loss-of-function mutation in
DMP1 resulted in hypophosphatemia and severe progressive
skeletal dysplasia characterized clinically by short stature,
joint pain, contractures, and immobilization of the spine and
radiographically by short and deformed long bones, significant
cranial hyperostosis, enthesopathies, and calcifications of the
paraspinal ligaments. Heterozygosity for the DMP1 mutation was
associated with mild hypophosphatemia but without clinical
evidence of skeletal dysplasia. The skeletal phenotype in ARHP
may be significantly more severe than that observed in other
forms of hypophosphatemic rickets.
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